Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D).

Details

Ressource 1Download: 29276388_BIB_D4CBAB5EC0EA.pdf (468.71 [Ko])
State: Public
Version: Final published version
License: CC BY-NC 4.0
Serval ID
serval:BIB_D4CBAB5EC0EA
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D).
Journal
Therapeutics and clinical risk management
Author(s)
Schernthaner G., Khunti K., Lotan C., Burnier M., Drexel H., Prázný M.
ISSN
1176-6336 (Print)
ISSN-L
1176-6336
Publication state
Published
Issued date
2017
Peer-reviewed
Oui
Volume
13
Pages
1569-1576
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Abstract
Type 2 diabetes (T2D) imposes a substantial disease burden, predominantly from cardiovascular disease (CVD), which accounts for >50% of deaths in this population and leads to a 12-year reduction in the life expectancy of a 60-year-old male patient with T2D and CVD compared with the general population. The results from mandatory cardiovascular outcome trials (CVOTs) are therefore of great interest in the field. The Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes meeting program aims to bring together experts from several associated disciplines to provide fair and balanced resources for those involved in the management of patients with T2D. This publication represents the opinions of the faculty on the key learnings from the meeting held in Vienna in the spring of 2017. In particular, we detail how data from the EMPA-REG OUTCOME® [cardiovascular outcomes trial of empagliflozin] and Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER®) (liraglutide) CVOTs can be practically interpreted across clinical specialities. It is hoped that this translation of CVOT data will achieve a dual treatment paradigm for the management of both raised glucose levels and CV risk in patients with T2D.

Keywords
CVOT, DPP-4 inhibitors, GLP-1 agonists, SGLT2 inhibitors, cardiovascular disease, type 2 diabetes
Pubmed
Web of science
Open Access
Yes
Create date
08/01/2018 17:56
Last modification date
20/08/2019 15:54
Usage data